Administration of DDD (2,2‐bis (Parachlorophenyl)‐1,1‐Dichloroethane) to Diabetics with Hyaline Vascular Changes and Hyperpolysaccharidemia

Törnblom, Nils

doi:10.1111/j.0954-6820.1956.tb14302.x

Cited by 20 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitotane (ortho,para,dichlorodiphenyl dichloroethane, o,p′-DDD, 2,2-bis[2-chlorophenyl-4-chlorophenyll-l,l-dichloroethane) is an adrenolytic drug derived from the insecticide dichlorodiphenyltrichloroethane, which has been used in treatment centers since 1959 [ 7 ]. Mitotane and its two active metabolites, o,p′-DDE (dichlorodiphenylethene) and o,p′-DDA (dichlorodiphenylacetate), have different mechanisms of actions: they act as antineoplastic agents, through the production of free radicals mediating cytotoxicity, and as inhibitors of adrenocortical steroidogenesis, blocking the cholesterol side-chain cleavage enzymes cytochrome P450 (CYP) 11A1 and 11B [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma

Allegra

Puglisi

Brescia

et al. 2021

Life

View full text Add to dashboard Cite

(1) Background: In clinical settings, data regarding sex are rarely investigated. In women, factors such as body size and composition, hormonal variations, metabolism, and access to care systems and therapy could strongly influence the pharmacological management and the outcome of the therapy. To underline this sex-related difference, we retrospectively collected data from adrenocortical carcinoma patients treated with mitotane, and then evaluated sex-related pharmacokinetics parameters. (2) Methods: A fully validated chromatographic method was used to quantify mitotane concentration in plasma collected from adult patients, also considering the active metabolite ortho,para,dichlorodiphenylethene (o,p’-DDE). Statistical analyses were used to evaluate the sex influence on drugs pharmacokinetics. (3) Results: We found that sex resulted as predictive factor of plasma mitotane and o,p’-DDE concentrations and significantly influenced the attainment of the therapeutic target of mitotane, implying that female sex could be a risk factor of treatment failure. (4) Conclusions: These results suggest that mitotane therapy should be modulated according to patient sex. Furthermore, the proposed approach could contribute to facilitating and disseminating sex-specific pharmacology.

show abstract

Section: Introductionmentioning

confidence: 99%